Keyphrases
Spinal muscular Atrophy
100%
Hepatotoxicity
100%
AVXS-101
100%
Onasemnogene Abeparvovec
100%
Liver
66%
Prednisolone
50%
Managed Access Programme
50%
Clinical Trials
33%
Adverse Events
33%
Gene Therapy
33%
Alanine Aminotransferase
33%
Aspartate Aminotransferase
33%
Laboratory Data
33%
Concomitant Medications
33%
Acute Liver Injury
33%
Bilirubin Concentration
33%
SMN1 Gene
33%
Immune Response
16%
Autosomal Recessive
16%
Clinical Data
16%
Liver Injury
16%
Treatment Duration
16%
Young children
16%
Motor Neuron Disease
16%
Hepatotoxic
16%
Result-oriented
16%
Inherited Condition
16%
Childhood-onset
16%
Risk Mitigation
16%
Drug-induced Liver Injury
16%
Potential Drugs
16%
Prednisolone Treatment
16%
Adverse Event Data
16%
Commercial Use
16%
Serum Aminotransferases
16%
Lay Summary
16%
Toxicology Studies
16%
Elevated Liver Function Tests
16%
Survival Motor Neuron
16%
Pharmacology, Toxicology and Pharmaceutical Science
Spinal Muscular Atrophy
100%
Hepatotoxicity
100%
Onasemnogene Abeparvovec
100%
Prednisolone
66%
Adverse Event
50%
Liver Injury
50%
Clinical Trial
33%
Aspartate Aminotransferase
33%
Alanine Aminotransferase
33%
Bilirubin
33%
Aminotransferase
16%
Toxic Hepatitis
16%
Motor Neuron Disease
16%
Survival Motor Neuron Protein
16%
Toxicology
16%